| |
 |
This is the category page. Below are all of the research programs that are associated with it
- Rheumatoid Arthritis -
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMBINATION WITH METHOTREXATE COMPARED WITH INFLIXIMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS CURRENTLY RESPONDING INADEQUATELY TO ETANERCEPT OR ADALIMUMAB (Protocol ACT4562g)
(1_20090210_118)
This is a Phase 2 Study for patients with active rheumatoid arthritis. Participants will be placed on one of two treatment arms. One arm consist of the study drug, Ocrelizumab given on Day 1 and Day 15 along with placebo at Day 1, Day 15, Week 6 and Week 14; or placed on the other arm and given Placebo at Day 1 and Day 15 along with Remicade at Day 1, Day 15, Week 6 and Week 14. Evaluation of the primary endpoint will be at Week 20. There will be multiple follow-up visits and eligible participants will be offered to enter an “open-label” treatment period. Participants who withdraw early from the study should enter a safety follow-up period. Participants will receive $150.00 at each treatment visit completed and $50.00 at all other visits to cover time and travel. Participants will also be asked to enroll in a DNA Repository Sub study, but you do not have to agree to be in the DNA study to participate in the main study.
- Rheumatoid Arthritis -
A STUDY OF ARTICULAR SYMMETRY IN RHEUMATOID ARTHRITIS (RA): AFRICAN AMERICANS COMPARED TO CAUCASIANS (Investigated Initiated Protocol)
(1_20081109_118)
This is an observational study designed to determine the prevalence of radiologically symmetrical joint involvement in African Americans compared to Caucasians with rheumatoid arthritis. Study participation will involve release of medical and demographic information and copies of x-rays taken as part of routine care.
- Rheumatoid Arthritis -
A PHASE 4, MULTICENTER, OPEN-LABEL, ASSESSOR-BLINDED, SWITCH STUDY OF THE EFFICACY AND SAFETY OF NFLIXIMAB (REMICADE®)IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO ARE RESPONDING INADEQUATELY TO ETANERCEPT (ENBREL®)OR ADALIMUMAB (HUMIRA®)(Protocol #C0168Z05)
(2_20080805_118)
This study is for patients diagnosed with active rheumatoid arthritis and will use FDA approved drugs. Participants will be followed for a period of 30 weeks during which time they will receive an infliximab (REMICADE) infusion at week #0, 2, 6, 14 and 22; assessment visits at week #10 and 26; and a follow-up/safety assessment at week #30. Participants will start at a dosage of 3mg and increased to 5mg at week #14 if not demonstrating a response. An additional increase from 5mg to 7mg will be given between weeks #14 and #22 if they still do not show a response.
- Rheumatoid Arthritis:
A SEAMLESS, PHASE 1 / 2, MULTIPLE ASCENDING DOSE, PROOF OF CONCEPT STUDY OF ATN-103 ADMINISTERED TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS ON A BACKGROUND OF METHOTREXATE
(2_20090808_118)
This is a Seamless Phase 1-2 Study. This study will consist of multiple ascending doses (MAD) for participants that have been diagnosed with Active Rheumatoid Arthritis. There will be a total of 6 treatment groups. Each participant will participate in the study for approximately 24 weeks, which includes up to 4 weeks screening period, a 16 week treatment period and a 4 week follow-up period. Participants will be given a total of 4 subcutaneous injections consisting of the study drug, ATN-103 or placebo; and will occur every 4 weeks.
|
|
